找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Optimal Use of Sandimmun in Endogenous Uveitis; D. BenEzra,R. B. Nussenblatt,P. Timonen Conference proceedings 1988Latest edition Sandoz L

[復(fù)制鏈接]
樓主: ARSON
11#
發(fā)表于 2025-3-23 10:45:35 | 只看該作者
12#
發(fā)表于 2025-3-23 14:16:02 | 只看該作者
results achieved so far with conventional therapy using systemic corticosteroids and cytotoxic agents, new treatment modalities have been sought. a) Start treatment with Sandimmun at initial doses of During the last four years, a total of over 300 patients 5 mg/kg/day. b) Use Sandimmun in combinatio
13#
發(fā)表于 2025-3-23 21:00:13 | 只看該作者
14#
發(fā)表于 2025-3-23 23:42:02 | 只看該作者
Present Experience with Sandimmun,ine, (97 patients) or placebo (12 patients). Most patients receiving Sandimmun had an initial loading dose of 5 to 10 mg/kg/day followed by a dose reduction according to ocular inflammatory activity and tolerability.
15#
發(fā)表于 2025-3-24 04:39:22 | 只看該作者
Introduction: Endogenous Uveitis, to the iris (iritis), the ciliary body (cyclitis) or both (iridocyclitis), the manifestation is coined anterior uveitis. Localization of the inflammatory reaction to the pars plana and peripheral fundus (pars planitis) as well as vitreous (vitritis) is coined intermediate uveitis, while posterior u
16#
發(fā)表于 2025-3-24 06:38:41 | 只看該作者
Conference proceedings 1988Latest editionndent studies all over the d) Taper Sandimmun dose as rapidly as possible to a world (over 200 patients) and in a masked manner in 4 maintenance dose below 5 mg/kg/day. e) Do not discontinue treatment with Sandimmun rap- independent controlled studies (over 100 patients re- idly.
17#
發(fā)表于 2025-3-24 12:24:38 | 只看該作者
18#
發(fā)表于 2025-3-24 15:51:40 | 只看該作者
19#
發(fā)表于 2025-3-24 20:32:39 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
20#
發(fā)表于 2025-3-25 00:38:40 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 18:47
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
务川| 古田县| 科尔| 阿鲁科尔沁旗| 秦安县| 南陵县| 布拖县| 鹿泉市| 饶平县| 新竹市| 惠州市| 光山县| 河南省| 射阳县| 永善县| 惠安县| 通化县| 夏津县| 鄢陵县| 白朗县| 泸定县| 长春市| 若羌县| 咸阳市| 孟津县| 雷波县| 达孜县| 宁城县| 十堰市| 宜君县| 西丰县| 宜宾市| 英超| 响水县| 和平县| 康定县| 华坪县| 布拖县| 桃江县| 泗水县| 洛宁县|